Search Results
Your search for ,UsE matches 11242 pages
Showing 1 - 50Setidegrasib in Advanced NSCLC and Pancreatic Cancer Harboring the KRAS p.G12D Variant
In a phase I trial reported in The New England Journal of Medicine, Park et al identified the toxicity profile and preliminary antitumor activity of setidegrasib, a first-in-class KRAS G12D–targeted protein degrader, in patients with previously treated advanced non–small cell lung cancer (NSCLC) or ...
Ablative Radiotherapy May Improves Outcomes for Patients With ‘Supermassive’ Intrahepatic Cholangiocarcinoma
A new study published by Jaoude et al in Clinical Cancer Research demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma. The retrospective study was led ...
Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Conflict
A new analysis from Phesi, a data analytics company, of 65,061 globally recruiting clinical trials across 186 countries has found that 4,361 studies—equivalent to 6.7% of all active trials—are impacted by disruption in the Middle East. Across a total of 356,699 recruiting investigator sites, 7,958...
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
Excluding skin cancers, colorectal cancer is the third most common cancer diagnosed in both men and women in the United States. According to the American Cancer Society, in 2025, about 154,270 individuals were diagnosed with colorectal cancer, and approximately 53,000 individuals died from the...
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
In a systematic review and meta-analysis published in JAMA Dermatology, Laiouar-Pedari et al evaluated the real-world diagnostic performance of artificial intelligence (AI)–assisted dermoscopy for melanoma detection. The study was undertaken to address a critical gap in the literature: while prior...
Presence of ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer may predict whether they are likely to experience relapse—especially when samples are taken after the patients have received treatments prior to surgery. Findings presented at the 15th European Breast Cancer...
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
An interpretable machine-learning framework, called PRE-Screen-HCC, may predict risk levels for developing hepatocellular carcinoma (HCC) more accurately than publicly available risk scores, according to findings from a large population-based multicentric study published in Cancer Discovery. “Our...
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-line setting, according to findings presented during the first European Society for Medical...
Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma
In a French phase II trial (GCO-001-NIPINEC) reported in the Journal of Clinical Oncology, Walter et al found that nivolumab plus ipilimumab showed some activity in patients with advanced gastroenteropancreatic (GEP) or lung large-cell neuroendocrine carcinoma (NEC) after failure of platinum-based...
Transdermal Estradiol Patches vs LHRH Agonists in Locally Advanced Prostate Cancer
As reported in The New England Journal of Medicine by Langley et al, a UK phase III trial (PATCH/STAMPEDE-1) has shown noninferiority in metastasis-free survival with the use of transdermal estradiol (tE2) patches vs luteinizing hormone–releasing hormone (LHRH) agonist treatment in men with locally ...
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precursor Asymptomatic Neoplasms by Group Effort Analysis–Smoldering Multiple Myeloma (PANGEA-SMM),...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
FDA Approves Relacorilant With Nab-Paclitaxel for Several Platinum-Resistant Gynecologic Cancers
On March 25, the U.S. Food and Drug Administration (FDA) approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
How AI Is Already Having a Significant Impact on Cancer Care
Three education sessions presented during the 2025 ASCO Annual Meeting showcased how artificial intelligence (AI) is quickly transforming cancer care from clinical trial planning and ambient scribes transcribing physician-patient conversations to therapeutic decision-making. The meeting also...
A Decade of Research Leads to New Guidance on Using Colony-Stimulating Factors in Anticancer Treatment
ASCO has published an updated guideline describing the latest evidence on using hematopoietic colony-stimulating factor (CSF) to support anticancer treatment, namely chemotherapy and stem cell transplantation.1 “We wanted to update these guidelines both to include the newer evidence as well as...
New First-Line Targeted Therapy Recommendations Among Updated ASCO Guidance on Gastroesophageal Cancer Management
ASCO has released a guideline update addressing advances in the use of immunotherapy and targeted therapy for the treatment of advanced gastroesophageal cancer.1 The guideline, last updated in 2023 to include first-line therapy recommendations for patients with biomarkers such as PD-L1 and HER2,...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Three AI-Enabled Analyses Highlight Context-Dependent Biomarkers in Early-Onset Colorectal Cancer
Biomarker discovery in colorectal cancer has traditionally focused on identifying molecular alterations with broad prognostic or predictive utility. However, evidence is increasingly suggesting that biomarkers do not have universal prognostic or predictive value across patient sets but instead...
Does Metformin Use Reduce the Risk of Esophageal Cancer?
Metformin use was linked to lower odds of developing esophageal squamous cell carcinoma in a Nordic population–based case-control study, according to findings published by Xie et al in JAMA Network Open. “This should prompt investigations of metformin as a preventive option in high-risk individuals ...
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
In a systematic review and meta-analysis reported in The Lancet Oncology, Varey et al found that patients undergoing sentinel node biopsy (SLNB) for melanoma had reduced risk of melanoma-specific mortality and disease recurrence vs those who did not undergo SLNB. Study Details The analysis included ...
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges. This annual survey on...
For Most Men With Prostate Cancer, Hormone Therapy With Postprostatectomy Radiotherapy Confers No Survival Benefit
Adding hormone therapy to postprostatectomy radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with very low prostate-specific antigen (PSA) levels before treatment. In the study, reported at the 2026 ASCO Genitourinary Cancers Symposium,1 men with...
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
As the incidence of cancer among reproductive-age people continues to increase in the United States—with approximately one out of every 1,000 pregnancies complicated by cancer—the Society for Maternal-Fetal Medicine (SMFM) has issued its first evidence-based clinical guidance for diagnosing and...
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients with locally advanced/metastatic urothelial carcinoma. The results from the randomized phase III...
Forgotten Lessons From South Africa
On March 10, 2000, it was a cold Friday morning in Washington, DC. As usual, we the oncology fellows and faculty crowded into a conference room at the NIH Clinical Center in Building 10 for our weekly conference. Before the session formally began, a senior faculty member walked in holding the New...
Kent Shih, MD, on Use of GEP for SLNB and Follow-up Planning in Melanoma
Kent Shih, MD, of Tennessee Oncology, shares three patient cases that illustrate how gene-expression profiling (GEP) in patients with melanoma helps shape the decision to proceed to sentinel lymph node biopsy (SLNB) and how often and thorough follow-up should be with medical oncology.
Kent Shih, MD, on Adjuvant Therapy in Melanoma: How Does GEP Testing Factor In?
Kent Shih, MD, of Tennessee Oncology, presents three patients cases that show how the use of gene-expression profile testing guides patient and practitioner decision-making when choosing the appropriate path of adjuvant treatment among individuals with melanoma.
Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia
New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has demonstrated that the method provided reliable and robust analytical performance with high sensitivity and specificity in detecting genetic alterations. In nearly 20% of cases,...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
AI Integration in Breast Cancer Screening Increases Detection Rate, Reduces Work Burden
Integration of artificial intelligence (AI) into screening workflows increased the detection of breast cancer by 10.4% in the United Kingdom, according to the results of the GEMINI study published in Nature Cancer. Additionally, use of AI in different workflows led to reductions in workload by up...
AI-Backed Liquid Biopsies Identify Liver Diseases
Building upon the foundation of liquid biopsy utility for the early detection of cancer, analysis of genome-wide cell-free DNA fragmentation with machine learning classification and modeling can also extend to the identification of liver cirrhosis and other chronic diseases, according to findings...
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1 “Mandatory and uniform reporting of all [venous and arterial...
Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence
Short-term exposure to low-dose vaginal estrogen therapy may relieve some symptoms of menopause for younger survivors of endometrial cancer without increasing the risk of endometrial cancer recurrence, according to findings from a study published in Menopause. “Early detection and improved,...
Research Suggests AI Pathology Models May Take Unreliable 'Shortcuts' to Identify Cancer Biomarkers
Artificial intelligence (AI) tools that detect molecular biomarker status from histologic images may be dependent upon correlational relationships with clinicopathologic features, preventing the models from learning the true causal effect of the biomarker, according to findings published in Nature...
Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer?
Circulating tumor DNA (ctDNA) may be used to predict metastatic risk and identify which patients with muscle-invasive bladder cancer are more likely to benefit from a bladder-sparing treatment approach, according to findings from the RETAIN trials presented at the 2026 ASCO Genitourinary Cancers...
Stereotactic vs Whole-Brain Radiation for Patients With Brain Metastases
Researchers have found that using a form of radiation therapy that targets individual tumors rather than whole-brain radiation is more optimal for patients with brain metastases, even if a larger number of tumors are present. These findings could help improve quality of life and cognitive function...
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
The results from the randomized phase III KEYNOTE-B15/EV-304 study show that neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rate in patients with muscle-invasive bladder cancer who were...
Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care
In time for the assigned deadline of February 23, 2026, medical societies, companies, health-care systems, and more have responded to a request for information from the Department of Health and Human Services (HHS) regarding the use of artificial intelligence (AI) in clinical practice. The Request...
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsored by a pharmaceutical company with an interest in prostate cancer treatments, extolled the virtues ...
SABCS 2025: Top Picks From a Breast Cancer Specialist
Among the high-quality abstract presentations at the annual San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his top picks for most...
Nomogram for Metastasis-Directed SBRT in PSMA PET-Staged Oligorecurrent Prostate Cancer
In a European retrospective study (PORTAL) reported in The Lancet Oncology, Soeterik et al developed a nomogram for predicting androgen-deprivation therapy (ADT)–free survival with metastasis-directed stereotactic body radiotherapy (SBRT) in patients with prostate-specific membrane antigen (PSMA)...
Lung Cancer: Variability of Open-Source AI Models in EGFR Mutation Prediction
In a study reported in JAMA Oncology, Rakaee et al identified the accuracy of open-source artificial intelligence (AI) models in predicting the presence of EGFR mutations in samples from patients with lung adenocarcinoma, including according to ancestral subgroups. Study Details The study included...
Introducing ASCO AI in Oncology
In February, ASCO and Conexiant launched ASCO AI in Oncology (ascoai.org), a digital platform dedicated to understanding how artificial intelligence (AI) is impacting cancer care. “Our goal with this hub is to empower oncology professionals with knowledge and the tools to adapt to a rapidly...
ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC
ASCO has published an updated guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), representing ASCO’s first Living Guideline in the area of prostate cancer and the first in any genitourinary (GU) cancer.1 “Guidelines will become less useful if...
AI-Selected Biomarker Guides First-Line Treatment Selection in Advanced Pancreatic Cancer
A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy options for patients with advanced pancreatic cancer, according to the results of a study presented in a poster at the 2026 ASCO...
First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL
The bispecific antibody odronextamab plus standard CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy yielded robust and durable responses in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL), based on the first results of the phase III OLYMPIA-3 study...
Inequalities in Use of Minimally Invasive Surgical Resection in Colon Cancer
In an English population–based study reported in The Lancet Oncology, Maringe et al found that inequalities in provision of minimally invasive surgical resection of colon cancer may be associated with poorer patient outcomes. Study Details The study involved data from patients diagnosed with stage...
AI Tool Classifies Pediatric Brain Tumors via Liquid Biopsy
Researchers developed a deep neural network, M-PACT, to identify and classify brain tumors in pediatric patients from the subnanogram-input cell-free DNA of methylomes, according to findings published in Nature Cancer. “This is a next-generation assay and computational framework that we’ve...
Stage II Melanoma: Adjuvant Pembrolizumab and Risk of New Skin Cancers
The incidence of new primary melanoma was similar among patients with completely resected stage IIB or IIC cutaneous melanoma who did vs did not receive adjuvant pembrolizumab, while nonmelanoma skin cancers were more common with placebo, according to a secondary analysis of the multicenter phase...
